Exelixis (EXEL) Interest Expenses (2010 - 2018)
Exelixis (EXEL) posted quarterly Interest Expenses of $2.0 million for Q2 2026, up 104.38% year-over-year from $958000.0 in Q2 2025, and up 5052.63% quarter-over-quarter from $38000.0 in Q1 2026.
Analysis
Exelixis (EXEL) Interest Expenses (2010 - 2018) Analysis & Trends
Exelixis' Interest Expenses history runs 17 years deep, the most recent figure standing at $2.0 million for Q2 2026.
- In Q2 2026, Interest Expenses rose 104.38% year-over-year to $2.0 million; the TTM figure through Apr 2026 stood at $2.0 million (up 104.38% YoY), while the FY2026 annual figure was $87.7 million, up 1.95% from the prior year.
- Interest Expenses for Q2 2026 stood at $2.0 million, up from $38000.0 in the prior quarter.
- The five-year high for Interest Expenses was $86.0 million in Q1 2025, with the low at $38000.0 in Q1 2026.
- The 5-year median for Interest Expenses is $8.5 million (2022), against an average of $21.1 million.
- The sharpest annual moves came in 2022 and 2026: Interest Expenses jumped 17481.1% in 2022, then sank 99.96% in 2026.
- Exelixis' Interest Expenses stood at $77.2 million in 2022, then gained by 7.47% to $83.0 million in 2023, then plunged by 98.62% to $1.1 million in 2024, then plunged by 93.3% to $77000.0 in 2025, then surged by 2442.86% to $2.0 million in 2026.
- Business Quant data shows EXEL's Interest Expenses at $2.0 million in Q2 2026, $38000.0 in Q1 2026, and $77000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Exelixis | 14.78 Bn | 13.94 Bn | 608.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 28, 2018 | -1,000.00 |
| Sep 28, 2018 | 1,000.00 |
| Jun 30, 2017 | 4.26 Mn |
| Mar 31, 2017 | 4.42 Mn |
| Dec 30, 2016 | 4.49 Mn |
| Sep 30, 2016 | 7.83 Mn |
| Jun 30, 2016 | 10.45 Mn |
| Mar 31, 2016 | 10.29 Mn |
| Sep 30, 2015 | 10.04 Mn |
| Jun 30, 2015 | 11.96 Mn |
| Mar 31, 2015 | 12.40 Mn |
| Dec 31, 2014 | 5.24 Mn |
| Sep 30, 2014 | 12.28 Mn |
| Jun 30, 2014 | 12.08 Mn |
| Mar 31, 2014 | 11.76 Mn |
| Dec 31, 2013 | 5.05 Mn |
| Sep 30, 2013 | 11.43 Mn |
| Jun 30, 2013 | 11.24 Mn |
| Mar 31, 2013 | 11.06 Mn |
| Dec 31, 2012 | 9.00 Mn |